IDH1 and central nervous system cancer: In another recent study, tumor evolution from IDH1-mutated low-grade gliomas to high-grade malignancy was examined by sequencing in 23 patients: interestingly, in six of the ten patients treated with temozolomide (TMZ) a massive accumulation of mutations (C–T transition) was observed, associated with progression to grade IV at recurrence [39].